# Tae Hun Kim > Tae Hun Kim is a Series B investor at Humax backing SaaS, Hotel and Software. See 5 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Humax](https://shizune.co/investors/profile/humax) - Total investments: 5 - Last investment: Jan 2022 - Lead investor: 60% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/tae-hun-kim-59513995/ Tae Hun Kim is a Series B investor at Humax focused on SaaS and Hotel. Tae Hun Kim is the Chief Executive Officer at Humax. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | SaaS | 1 | 20% | | Hotel | 1 | 20% | | Software | 1 | 20% | | Biopharma | 1 | 20% | | Mobile Apps | 1 | 20% | 15 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series B | 2 | 40% | | Seed | 1 | 20% | | Corporate Round | 1 | 20% | | Venture - Series Unknown | 1 | 20% | ### Country | Country | Investments | Share | | --- | --- | --- | | France | 1 | 20% | | South Korea | 1 | 20% | | United States | 1 | 20% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | AZMT | Hotel space development startup | | Venture - Series Unknown | Jan 24, 2022 | | | LANE4 | Lane4 develops AI-based sports analytics and motion analysis software for athletes and training environments. The company provides computer vision technology, performance tracking systems, biomechanics analysis, and data-driven coaching tools used in sports training and athletic performance evaluation. | $2.5M | Seed | Oct 21, 2021 | | | Acticor Biotech | Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $7.7M | Series B | Nov 06, 2019 | | | FleetUp | FleetUp applies big data technologies to fleet management with a patented solution that enables companies to maximize profitability, improve driver safety, and comply with current and upcoming regulations more effectively. FleetUp is offered as a Software-as-a-Service (SaaS), with hardware, cellular, and infrastructure costs bundled into theoffering with easy-to-use applications for both Android and iOS devices. | $20M | Corporate Round | Feb 27, 2018 | | | FleetUp | FleetUp applies big data technologies to fleet management with a patented solution that enables companies to maximize profitability, improve driver safety, and comply with current and upcoming regulations more effectively. FleetUp is offered as a Software-as-a-Service (SaaS), with hardware, cellular, and infrastructure costs bundled into theoffering with easy-to-use applications for both Android and iOS devices. | $5M | Series B | Apr 11, 2017 | | 5 of 5 investments shown. ## Co-investors - [Karista](https://shizune.co/investors/profile/karista) — VC Fund, 1 deal together - [Newton Biocapital](https://shizune.co/investors/profile/newton-biocapital) — VC Fund, 1 deal together - [GO CAPITAL](https://shizune.co/investors/profile/ouest-ventures) — VC Fund, 1 deal together - [SJ Investment Partners](https://shizune.co/investors/profile/sj-investment-partners) — VC Fund, 1 deal together ## About Humax VC Fund 1 contacts available at Humax. | Name | Title | Profile | | --- | --- | --- | | Tae Hun Kim | CEO | https://shizune.co/investors/profile/tae-hun-kim | ## Similar investors ### Similar stage - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund - [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund ## FAQ ### What does Tae Hun Kim invest in? Tae Hun Kim invests primarily in SaaS, Hotel and Software startups, most often at Series B and Seed stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Tae Hun Kim last invest? The most recent investment recorded for Tae Hun Kim closed in Jan 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co